ClinicalTrials.gg
CompletedNCT06880640Updated Oct 2, 2026

Affect-based Impulsivity in Borderline Personality Disorder

An interventional study of Stress Induction in Borderline Personality Disorder (BPD) and Healthy Controls Group - Age and Sex-matched, sponsored by University of North Carolina, Chapel Hill. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by University of North Carolina, Chapel Hill · Not applicable, Interventional, and Basic science

How we know

Updated Oct 2, 2026Now CompletedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
76
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in Borderline Personality Disorder with a site in United States — 15 open to participants now, 17 under way, none of them phase 3. Borderline Personality Disorder · United States.

Enrollment
29th of 71
76 · median 56
Started
2025
with 3 others
No phase
39 of 81
9 open now
Registered
76th of 81
by date

Among the 81 studies in Borderline Personality Disorder with a site in United States, this one is the 29th largest by enrollment of the 71 interventional ones that give a count, is one of 4 that started in 2025, is one of 39 with no phase, and was the 76th registered.

Borderline Personality Disorder

279 studies on the registry are indexed under Borderline Personality Disorder; 70 are open to participants now.

Browse Borderline Personality Disorder studies →

Open to participants now

15 of the 81 studies in Borderline Personality Disorder with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 49 Borderline Personality Disorder studies recruiting now, 18 (37%) set no upper age limit and 30 (61%) stop at 75 or younger; 7 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Borderline Personality Disorder with a site in United States, or all of them as a file.
02

Study summary

The purpose of this research study is to investigate how personality traits and neuroendocrine systems relate to decision-making patterns in individuals 18-45 years old. The main question it aims to answer is how neuroendocrine activity impacts decision-making.

Participants will complete online behavioral tasks, a stress induction procedure, self-report surveys, and a cognitive assessment. During the session, psychophysiological measures will be collected, including electrocardiogram (ECG) and cardiac impedance (ICG) to monitor heart rate and blood flow, as well as electrodermal activity (EDA), blood drop samples, and saliva collection to assess nervous system activity.

03

Conditions studied

  • Borderline Personality Disorder (BPD)
  • Healthy Controls Group - Age and Sex-matched
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Borderline Personality Disorder (BPD) group:

  • Score of 38 or higher on Personality Assessment Inventory-Borderline Scale (PAI-BOR)
  • Participants in the BPD group will be primarily recruited from the two

DEPENd lab studies that maintain large samples of BPD participants. To ensure maximal similarity between BPD participants recruited from other DEPENd lab studies and BPD participants recruited through other recruitment sources, the investigators will use the same criteria for the BPD group in the current study as the criteria used in the other DEPENd lab studies. BPD participants in the two DEPENd lab studies from which the investigators will be recruiting must meet the following criteria:

  1. 3+ BPD symptoms, one of which must be affective instability, per clinical interview
  2. Participants must score at least 80 on the Reynolds Intellectual Screening Test (RIST).

Health Control (HC) Group:

  • Score of 12 or lower on PAI-BOR
  • Score below 50th percentile on World Health Organization Disability Assessment Schedule (WHODAS)
  • Absence of any current or lifetime psychiatric disorder, including personality disorders as determined by diagnostic interviews (SIDP and SCID), if the participant had participated in the lab's other studies (IRB Nos. 20-1735 and 21-0602).

Combined Inclusion Criteria:

  • Ages 18-45
  • Provision of signed and dated form
  • Stated willingness to comply with all study procedures and lifestyle considerations and availability for the duration of the study
  • Willingness to participate in all components of the study
  • Participants must be able to speak, understand and read English.
  • Participants must have at least 20/40 visual acuity (correct or uncorrected).

Exclusion criteria

Exclusion Criteria:

  • Use of as needed antihypertensive agents within 12 hours prior to lab visit
  • Inability to refrain from using as needed psychotropic medications for 12 hours prior to lab visit
  • History of psychotic disorder, Bipolar I disorder, autism spectrum disorder, reactive attachment disorder, pervasive developmental disorder, motor disorder, head injury, mental retardation, neurological disorder, or current substance dependence
  • Family history of Bipolar I disorder in a first degree relative.
  • Participants are also excluded for any of the following: cardiac pacemaker, aneurysm clip, cochlear implants, pregnancy, shrapnel, history of metal fragments in eyes, neurostimulators, weight of 250 lbs. or more, or claustrophobia.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    Stress

    Participants will undergo a controlled stress induction approximately 1 hour and 35 minutes into Session 1.

    Behavioral: Stress Induction

Interventions

  • BehavioralStress Induction

    Participants will complete the Trier Social Stress Test to induce stress, which includes a public speaking simulation and mental arithmetic.

    Also known as: Trier Social Stress Test (TSST)

06

What researchers measure

Primary outcomes

  1. Goal-directed decision-making in the Social Decision Tree Task (SDTT)

    Measured by choice behavior in SDTT, which is based on the decision tree framework. After each action, participants receive feedback about the effect of that action and the extent to which it added to or took away from their points. If participants make a given choice, the subsequent actions that they can choose are different than if they were to initially make a different choice. An action in SDTT is goal-directed if the possible net gain an individual can earn before the end of the current epoch (a "day" in the SDTT) is equal to or higher than the amount they could gain by choosing the alternative action. The investigators will subset trials so that 1 is coded as choosing the immediately valuable action at the expense of the optimal and 0 is coded as choosing the optimal at the expense of the immediately valuable action. This outcome variable is binary.

    Time frame: Collected for 40 minutes ~2 hours into one-time study visit

Secondary outcomes

  1. Bias toward social actions in the Social Decision Tree Task (SDTT)

    Measured by choice behavior in SDTT, which is based on the decision tree framework. An action in SDTT is defined as social if it is paired with a visual cue with a face on it and non-social if not. This outcome variable is binary.

    Time frame: Collected for 40 minutes ~2 hours into one-time study visit

Other outcomes

  1. Change in salivary cortisol

    The investigators will collect a saliva sample to measure baseline salivary cortisol at the beginning of the session. They will collect a second saliva sample 10 minutes after the stress induction concludes. They will measure cortisol levels in both samples through an assay. The investigators will calculate the change in salivary cortisol by subtracting the measured cortisol in the first saliva sample (collected at baseline) from the measured cortisol in the second saliva sample (collected 10 minutes after the stress induction). Salivary cortisol is measured as nmol/L. Salivary cortisol expected to generally be below 200 nmol/L.

    Time frame: Collected shortly after the participant consents into the study (~20 minutes into the one-time study visit) and 20 minutes after stress induction concludes (~2 hours into one-time study visit)

07

Study locations

1 site
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27514, United States
08

References and documents

Publications

  • Huys QJ, Eshel N, O'Nions E, Sheridan L, Dayan P, Roiser JP. Bonsai trees in your head: how the pavlovian system sculpts goal-directed choices by pruning decision trees. PLoS Comput Biol. 2012;8(3):e1002410. doi: 10.1371/journal.pcbi.1002410. Epub 2012 Mar 8. PubMed 22412360 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Deidentified individual data that supports the results will be shared beginning 9 to 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with the University of North Carolina at Chapel Hill (UNC).

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Beginning 9 and continuing for 36 months following publication

Access criteria: Investigator who proposes to use the data has approved IRB, IEC, or REB and an executed data use/sharing agreement with UNC.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2025 to primary completion in Aug 2026, 10 months.

Of 106 non-industry interventional studies with no phase under Borderline Personality Disorder, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 54. This study's 10 months is below that.

Counting every sponsor, half of 108 studies reached it within 35 months; a quarter within 24 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2025
First posted
Mar 18, 2025
StartActual
Sep 21, 2025
Primary completionActual
Aug 13, 2026
CompletionActual
Aug 13, 2026
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 2, 2026
Enrollment
106 (estimated)→76 (actual)
Oct 2, 2026
Documents
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Recruiting→Completed
    Documents Informed consent form ↗ posted
    Enrollment 106 (estimated)→76 (actual)
    + 3 other changes: date precision, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06880640
Collaborators
North Carolina Translational and Clinical Sciences Institute
Responsible party
Sponsor
First posted
Mar 18, 2025
Start date
Sep 21, 2025
Primary completion
Aug 13, 2026
Completion
Aug 13, 2026
Last update
Oct 2, 2026

Study contacts

Keely Muscatell, PhD
principal investigator · University of North Carolina, Chapel Hill

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion